NEW ORLEANS — At the American Society of Cataract and Refractive Surgery meeting, Amar Agarwal, MS, FRCS, FRCOphth, discusses the advantages of the trocar anterior chamber maintainer device for a variety of intraocular procedures.
Uncategorized
Uncategorized
Use of diagnostic, therapeutic tools improves dry eye detection and management
The TearScience LipiView imaging device and LipiFlow system provide an efficient means to diagnose, treat and monitor progress in patients with evaporative dry eye syndrome and is a worthwhile investment for every ophthalmology practice, according to one surgeon.“I am not a dry eye specialist, but thanks to this technology, I have learned to look at dry eye from a different perspective, to learn more and to consider it as a treatable condition,” Matteo Piovella, MD, OSN Europe Edition Board Member, said.
Uncategorized
SanBio Granted Key Patent in Treatment for Macular Degeneration
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–SanBio, Inc., a scientific leader in regenerative medicine, today announced it has been granted a key patent by the United States Patent and Trademark Office (USPTO) covering its proprietary modified stem cells, …
Uncategorized
Global Choroidal Neovascularization Pipeline Review, H1 2016 – Analysis, Technologies & Forecasts – Key Vendors: Affitech, Genentech, Mabion – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Choroidal Neovascularization – Pipeline Review, H1 2016” report to their offering. The report provides comprehensive information on the therapeutics under development for …
Uncategorized
VIDEO: Surgeon proposes new hypothesis for pathogenesis of keratoconus
PARIS — At the meeting of the French Society of Ophthalmology, Michael Assouline, MD, hypothesizes that the pathogenesis of keratoconus may involve genetic factors leading to dysregulation of the emmetropization process, much like the one identified for high myopia.
サンバイオ、再生細胞薬SB623の網膜変性疾患用途特許を取得
米国カリフォルニア州マウンテンビュー–(BUSINESS WIRE)–（ビジネスワイヤ） — 再生細胞薬の開発・製造を手掛ける当社グループ（サンバイオ株式会社およびその子会社であるSanBio Inc.）は、この度、独自に開発を進めている再生細胞薬SB623（以下、「本剤」）について、網膜変性疾患を対象とした特許を米国特許商標局（USPTO）から取得しましたのでお知らせします。当社は、中枢神経系において神経再生を促進する再生細胞薬SB623を開発しており、網膜変性疾患を含む神経細胞が関与する様々な疾患に対する治療薬の提供を目指しています。 2016年5月3日に取得が完了した特許（米国特許番号No. 9,326,999 B2）は、再生細胞薬SB623の用途特許で、光受容体機能の向上を促進することで網膜変性疾患を治療するというものです。網膜色素変性や加齢黄斑変性をはじめとする網膜変性疾患は、視細胞や網膜色素上皮が変性することで視力が減弱します。網膜変性疾患の中でも網膜色素変性症や、萎縮型加齢黄斑変性は有効な治療法がなく、また最終的には失明に至る場合もあるため、有効な治療法が求められ